Abstract
Abnormal indices of cell cycle regulation have been reported in multiple psychiatric disorders. Though reports specific to obsessive compulsive disorder (OCD) are scant, numerous studies have highlighted partly common underlying biology in psychiatric disorders, cell cycle regulation being one such process. In this study, we therefore aimed to explore cell cycle in OCD. To the best of our knowledge, this is the first study to investigate these effects in OCD. We also evaluated the effect of in vitro fluoxetine, commonly used serotonin reuptake inhibitor (SRI) in OCD patients, on cell cycle regulation. The effects of both disease (OCD) and treatment (SRI) were assessed using lymphoblastoid cell lines (LCLs), derived from OCD patients and healthy controls, as a model system. LCLs were treated with 10μM of fluoxetine for 24 hours, and the percentage of cells in each phase of the cell cycle was determined by flow cytometry. We observed a lower proportion of cells in the G2/M phase in OCD cases than controls. The findings suggest that cell cycle dysregulation could be peripheral cellular phenotype for OCD. Among cases, all of whom had been systematically characterized for SRI treatment response, LCLs from non-responders to SRI treatment had a lower proportion of cells in G2/M phase than responders.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study has been supported by various research grants - from the Department of Biotechnology, Government of India, as part of the Accelerator Program for Discovery in Brain Disorders using Stem cells (ADBS); the Department of Science & Technology (by the DST-INSPIRE Program Faculty grant) to BV; and the OCD Genetics Study (Grant no.GIA/38/2014-DHR) by the Indian Council Medical Research (ICMR), Ministry of Health & Family Welfare, Government of India to BV and YCJR. The authors PM, SN, RKN, PP, SB; RS were/are supported by the ADBS Program
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Author Note: Pravallika Manjappa is currently affiliated to the BonePainII Innovative Training Network - Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom; Tulika Shukla is currently affiliated to: Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, India
Discussion section updated. Further analyses done - represented in Table 2
Data Availability
Available by contacting the corresponding author
